Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs

Current Eye Research

Volumn 35, Issue 7, 2010, Pages 537-552

  Souto, Eliana B ^a,b   Doktorovova, Slavomira ^b   Gonzalez Mira, Elisabet ^c   Egea, Maria Antonia ^c   Garcia, Maria Luisa ^c  

^a UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Lipid nanoparticles; Nanostructured lipid carriers; Non steroidal anti inflammatory drugs; Ocular delivery; Solid lipid nanoparticles

Indexed keywords

ANTIINFLAMMATORY AGENT; BROMFENAC; CORTICOSTEROID; CYCLOSPORIN A; DECANOIC ACID; DEXAMETHASONE; DIACYLGLYCEROL; DICLOFENAC; FLUOCINOLONE ACETONIDE; FLUOROMETHOLONE; FLURBIPROFEN; GLYCEROL PALMITOSTEARATE; IBUPROFEN; INDOMETACIN; KETOROLAC; LINOLEIC ACID; MEDRYSONE; MELANIN; MONOACYLGLYCEROL; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; POLOXAMER; PRANOPROFEN; PREDNISOLONE; PROPYLENE GLYCOL; RIMEXOLONE; SOLID LIPID NANOPARTICLE; SUPROFEN; TRIAMCINOLONE; UNINDEXED DRUG; DRUG CARRIER; LIPID; NANOPARTICLE;

ALLERGIC CONJUNCTIVITIS; ANTERIOR EYE CHAMBER; ANTIBIOTIC THERAPY; BLOOD EYE BARRIER; BLOOD RETINA BARRIER; CATARACT; CHOROID; CILIARY BODY; COMBINATION CHEMOTHERAPY; CONJUNCTIVA; CORNEA; CORNEA EPITHELIUM; CORNEAL SCLERAL MELTING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INSTILLATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG TRANSPORT; DRY EYE; EYE DISCOMFORT; EYE DISEASE; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; EYE SURGERY; FEASIBILITY STUDY; GLAUCOMA; HUMAN; HYDROPHILICITY; INFLAMMATION; INTRAOCULAR HYPERTENSION; IRIS; KERATOCONJUNCTIVITIS; KERATOCONJUNCTIVITIS SICCA; KERATOPATHY; LIPOPHILICITY; MIOSIS; MYDRIASIS; OPTIC NERVE INJURY; PAIN; POSTERIOR EYE CHAMBER; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PTOSIS; PUNCTATE STAINING; REFRACTIVE SURGERY; REPEATED DRUG DOSE; RETINA; RETINA MACULA EDEMA; REVIEW; SCLERA; SEASONAL ALLERGIC CONJUNCTIVITIS; SJOEGREN SYNDROME; UVEA; VISUAL DISORDER; VITREOUS BODY; WOUND HEALING IMPAIRMENT; ANIMAL; BIOAVAILABILITY; DRUG EFFECTS; EYE; EYE DISEASES;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; EYE; EYE DISEASES; FEASIBILITY STUDIES; HUMANS; LIPIDS; NANOPARTICLES;

EID: 77954416176     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713681003760168     Document Type: Review

References (130)

1. Hornof M, Toropainen E, Urtti A. Cell culture models of the ocular barriers. Eur J Pharm Biopharm. 2005;60:207-225. (Pubitemid 40804562)
2. Kaur IP, Kanwar M. Ocular preparations: The formulation approach. Drug Dev Ind Pharm. 2002;28:473-493. (Pubitemid 34680549)
3. Ali Y, Lehmussaari K. Industrial perspective in ocular drug delivery. Adv Drug Deliv Rev. 2006;58:1258-1268.
4. Barar J, Javadzadeh AR, Omidi Y. Ocular novel drug delivery: Impacts of membranes and barriers. Expert Opin Drug Deliv. 2008;5:567-581. (Pubitemid 351877434)
5. Urtti A. Challenges and obstacles of ocular pharmacokinet-ics and drug delivery. Adv Drug Deliv Rev. 2006;58:1131-1135.
6. Hughes PM, Olejnik O, Chang-Lin J-E, et al. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005;57:2010-2032. (Pubitemid 41740793)
7. Kim SH, Lutz RJ, Wang NS, et al. Transport barriers in trans-scleral drug delivery for retinal diseases. Ophthalmic Res. 2007;39:244-254.
8. Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Surv Ophthalmol. 2005;50:167-182. (Pubitemid 40340948)
9. Kaur IP, Garg A, Singla AK, et al. Vesicular systems in ocular drug delivery: An overview. Int J Pharm. 2004;269:1-14. (Pubitemid 38035207)
10. Ammar HO, Salama HA, Ghorab M, et al. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS Pharm Sci Tech. 2009;10:808-819.
11. Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci. 1996;85:530-536. (Pubitemid 26153217)
12. Gaudana R, Jwala J, Boddu SH, et al. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26:1197-1216.
13. Kapoor Y, Chauhan A. Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels. Int J Pharm. 2008;361:222-229.
14. Vandamme TF. Microemulsions as ocular drug delivery systems: Recent developments and future challenges. Prog Retin Eye Res. 2002;21:15-34.
15. Le Bourlais C, Acar L, Zia H, et al. Ophthalmic drug delivery systems\Recent advances. Prog Retin Eye Res. 1998;17:33-58. (Pubitemid 28040752)
16. Moghimi SM, Vega E, García ML, et al. Polymeric nanopar-ticles as drug carriers and cotrolled release implant devices. In: VP Torchilin (Ed.). Nanoparticulates as Drug Carriers. London: Imperial College Press, 2006; pp. 29-42.
17. Cheng Y, Xu Z, Ma M, et al. Dendrimers as drug carriers: Applications in different routes of drug administration. J Pharm Sci. 2008;97:123-143.
18. Vandamme TF, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release. 2005;102:23-38. (Pubitemid 40093773)
19. Marano RJ, Toth I, Wimmer N, et al. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: A long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther. 2005;12:1544-1550. (Pubitemid 41541772)
20. Cavalli R, Gasco MR, Chetoni P, et al. Solid lipid nanopar-ticles (SLN) as ocular delivery system for tobramycin. Int J Pharm. 2002;238:241-245. (Pubitemid 34457892)
21. del Pozo-Rodriguez A, Delgado D, Solinis MA, et al. Solid lipid nanoparticles: Formulation factors affecting cell trans-fection capacity. Int J Pharm. 2007;339:261-268. (Pubitemid 46977611)
22. del Pozo-Rodriguez A, Delgado D, Solinís MA, et al. Solid lipid nanoparticles for retinal gene therapy: Transfec-tion and intracellular traffcking in RPE cells. Int J Pharm. 2008;360:177-183.
23. Attama AA, Reichl S, Muller-Goymann CC. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm. 2008;355:307-313.
24. Li X, Nie SF, Kong J, et al. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008;363:177-182.
25. Gokce EH, Sandri G, Bonferoni MC, et al. Cyclosporine A loaded SLNs: Evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm. 2008;364:76-86.
26. Niu M, Shi K, Sun Y, et al. Preparation of CyA-loaded solid lipid nanoparticles and application on ocular preparations. J Drug Deliv Sci Technol. 2008;18:293-297.
27. El-Harazi SM, Feldman RM. Control of intra-ocular infammation associated with cataract surgery. Curr Opin Ophthalmol. 2001;12:4-8. (Pubitemid 32113605)
28. Sunaric-Megevand G, Pournaras CJ. Current approach to postoperative endophthalmitis. Br J Ophthalmol. 1997;81:1006-1015. (Pubitemid 27493991)
29. O'Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin. 2005;21:1131-1137.
30. Schalnus R. Topical nonsteroidal anti-infammatory therapy in ophthalmology. Ophthalmologica. 2003;217:89-98. (Pubitemid 36237702)
31. Korenfeld M. Difuprednate: Changing the landscape of ocular pharmacology. Expert Rev Ophthalmol. 2008;3: 619-625.
32. Noecker RJ, Golightly SF. Pharmacology in ocular surgery. J Ophthalmic Nurs Technol. 1999;18:101-108.
33. Ahuja M, Dhake A, Sharma S, et al. Topical ocular delivery of NSAIDs. AAPS J. 2008;10:229-241.
34. Flach AJ. Topical nonsteroidal antiinfammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42:1-11.
35. Heier JS, Topping TM, Baumann W et al. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000;107:2034-2038
36. Raizman M.Corticosteroid therapy of eye disease. Fifty years later. Arch Ophthalmol. 1996;114:1000-1001. (Pubitemid 26271468)
37. Gaynes BI, Fiscella R. Topical nonsteroidal anti-infamma-tory drugs for ophthalmic use: A safety review. Drug Safety. 2002;25:233-250. (Pubitemid 34569358)
38. Pignatello R, Bucolo C, Ferrara P, et al. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci. 2002;16:53-61. (Pubitemid 34756782)
39. Pignatello R, Bucolo C, Spedalieri G, et al. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials. 2002;23:3247-3255. (Pubitemid 34522137)
40. Vega E, Gamisans F, Garcia ML, et al. PLGA nanospheres for the ocular delivery of furbiprofen: Drug release and interactions. J Pharm Sci. 2008;97:5306-5317.
41. Vega E, Egea MA, Valls O, et al. Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J Pharm Sci. 2006;95:2393-2405. (Pubitemid 44726380)
42. Sashmal S, Mukherjee S, Ray S, et al. Design and optimization of NSAID loaded nanoparticles. Pak J Pharm Sci. 2007;20:157-162.
43. Ghate D, Edelhauser HF. Barriers to glaucoma drug delivery. J Glaucoma. 2008;17:147-156. (Pubitemid 351412405)
44. Watsky MA, McDermott ML, Edelhauser HF. In vitro cor-neal endothelial permeability in rabbit and human: The effects of age, cataract surgery and diabetes. Exp Eye Res. 1989;49:751-767.
45. Wang W, Sasaki H, Chien DS, et al. Lipophilicity infuence on conjunctival drug penetration in the pigmented rabbit: A comparison with corneal penetration. Curr Eye Res. 1991;10:571-579.
46. Bucolo C, Maltese A, Drago F. When nanotechnology meets the ocular surface. Expert Rev Ophthalmol. 2008;3:325-332. (Pubitemid 351983994)
47. Behar-Cohen FF, BenEzra D, Einmahl S. Challenges of intraocular drug delivery. Eur Pharm Rev. 2001;6:35-40.
48. Velez G, Whitcup SM. New developments in sustained release drug delivery for the treatment of intraocular disease. Br J Ophthalmol. 1999;83:1225-1229. (Pubitemid 29511801)
49. Liu DT, Lee VY, Lam PT, et al. Acyclovir-induced nephro-toxicity in a patient with acute retinal necrosis. Hong Kong Med. J 2007;13:155-156. (Pubitemid 46556779)
50. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci. 2000;41: 961-964. (Pubitemid 30187528)
51. Unger WG. Review: Mediation of the ocular response to injury. J Ocul Pharmacol. 1990;6:337-353.
52. Jaanus SD, Lesher GA.Anti-infammatory drugs. In: JD Bartlett (Ed.). Clinical Ocular Pharmacology. Oxford: Butter-worth-Heineman, 1995; pp. 303-314.
53. Campbell WB, Halushka PV.Lipid derived autocoids. In: LE Hardman. Goodman and Gilman's. The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill, 1990; pp. 601-633.
54. Gaudio P. A review of evidence guiding the use of corticos-teroids in the treatment of intraocular infammation. Ocular Immunol Infamm. 2004;12:169-192. (Pubitemid 39424881)
55. Jaffe GJ, Ben-Nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024-2033.
56. Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina. 2000;20:402-403.
57. Samudre SS, Lattanzio FA, Jr, Williams PB, et al. Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther. 2004;20:533-547. (Pubitemid 39628498)
58. Recasens JF, Green K. Effects of endotoxin and anti-infam-matory agents on superoxide dismutase in the rabbit iris. Ophthalmic Res. 1990;22:12-18. (Pubitemid 20102259)
59. Bron A, Denis P, Hoang Xuan TC, et al. The effects of Rimex-olone 1% in postoperative infammation after cataract extraction. A double-masked placebo-controlled study, Eur J Ophthalmol. 1998;8:16-21. (Pubitemid 28197830)
60. Pfugfelder SC. Antiinfammatory therapy for dry eye. Am J Ophthalmol. 2004;137:337-342.
61. Nagelhout TJ, Gamache DA, Roberts L, et al. Preservation of tear flm integrity and inhibition of corneal injury by dexam-ethasone in a rabbit model of lacrimal gland infammation-induced dry eye. J Ocul Pharmacol Ther. 2005;21:139-148. (Pubitemid 40577969)
62. Yang CQ, Sun W, Gu YS. A clinical study of the effcacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B. 2006;7:675-678.
63. Ferguson VM, Spalton DJ. Recovery of the blood-aqueous barrier after cataract surgery. Br J Ophthalmol. 1991;75: 106-110.
64. Jonas JB, Kreissig I, Degenring RF. Cataract surgery after intravitreal injection of triamcinolone acetonide. Eye. 2004;18:361-364. (Pubitemid 38585008)
65. Young S, Larkin G, Branley M, et al. Safety and effcacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol. 2001;29:2-6. (Pubitemid 32170788)
66. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin. 1992;10:505-512.
67. Reddy MS, Suneetha N, Thomas RK, et al. Topical diclofenac sodium for treatment of postoperative infammation in cataract surgery. Indian J Ophthalmol. 2000;48:223-226. (Pubitemid 32221965)
68. Leonardi A, Borghesan F, Faggian D, et al. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol. 2000;129:151-158. (Pubitemid 30089273)
69. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002;47(Suppl.1):203-218. (Pubitemid 35232234)
70. Price MO, Price FW.Effcacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr Med Res Opin. 2004;20: 2015-2019.
71. Bandare BM, Sankaridurg PR, Willcox MD. Non-steroidal antinfammatory agents decrease bacterial colonization of contact lenses and prevent adhesion to human corneal epithelial cells. Curr Eye Res. 2004;29:245-251.
72. Aragona P, Stilo A, Ferreri F, et al. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjogren's syndrome patients. Eye. 2005;19: 535-539. (Pubitemid 40711706)
73. Walters T, Raizman M, Ernest P, et al. In vivo pharma-cokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007;33:1539-1545. (Pubitemid 47299180)
74. Acosta MC, Luna C, Graff G, et al. Comparative effects of the nonsteroidal anti-infammatory drug nepafenac on corneal sensory nerve fbers responding to chemical irritation. Invest Ophthalmol Vis Sci. 2007;48:182-188. (Pubitemid 47251401)
75. Thaller VT, Kulshrestha MK, Bell K. The effect of pre-operative topical furbiprofen or diclofenac on pupil dilatation. Eye. 2000;14:642-645.
76. Gulkilik G, Kocabora S, Taskapili M, et al. Cystoid macular edema after phacoemulsifcation: Risk factors and effect on visual acuity. Can J Ophthalmol. 2006;41:699-703. (Pubitemid 46113022)
77. Benezra D. The role of cyclosporin eye drops in ocular infammatory diseases. Ocul Immunol Infamm. 1993;1: 159-162.
78. Alzamora-Barrios B, Guerra L, Jiménez H, et al. Treatment of severe queratitis sicca and ocular infammation with cyclosporine A therapy. Rev Soc Peru Med Interna. 2007;20: 145-148.
79. Schechter BA. Ketorolac during the induction phase of cyclosporin-A therapy. J Ocul Pharmacol Ther. 2006;22: 150-154.
80. Mohan N, Gupta V, Tandon R, et al. Topical ciprofoxa-cin-dexamethasone combination therapy after cataract surgery\Randomized controlled clinical trial. J Cataract Refract Surg. 2001;27:1975-1978. (Pubitemid 33136178)
81. Gasco MR, Saettone MF, Zara GP. Pharmaceutical compositions suitable for the treatment of ophthalmic diseases. US Patent Application 2006/0024374; 2006.
82. Huang ZR, Hua SC, Yang YL, et al. Development and evaluation of lipid nanoparticles for camptothecin delivery: A comparison of solid lipid nanoparticles, nanostruc-tured lipid carriers, and lipid emulsion. Acta Pharmacol Sin. 2008;29:1094-1102.
83. Olbrich C, Scholer N, Tabatt K, et al. Cytotoxicity studies of Dynasan 114 solid lipid nanoparticles (SLN) on RAW 264.7 macrophages-impact of phagocytosis on viability and cytokine production. J Pharm Pharmacol. 2004;56: 883-891. (Pubitemid 38885982)
84. Shah KA, Joshi MD, Patravale VB. Biocompatible micro-emulsions for fabrication of glyceryl monostearate solid lipid nanoparticles (SLN) of tretinoin. Journal of Biomedical Nanotechnology. 2009;5:396-400.
85. Caboi F, Lazzari P, Pani L, et al. Effect of 1-butanol on the microstructure of lecithin/water/tripalmitin system. Chem Phys Lipids. 2005;135:147-156. (Pubitemid 40744735)
86. Bunjes H, Koch MHJ, Westesen K. Infuence of emulsifers on the crystallization of solid lipid nanoparticles. J Pharm Sci. 2003;92:1509-1520. (Pubitemid 36792763)
87. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery\A review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-177. (Pubitemid 30326695)
88. Souto EB, Müller RH.Lipid nanoparticles (solid lipid nanoparticles and nanostructured lipid carriers) for cosmetic, dermal and transdermal applications. In: D Thassu, M Deleers, Y Pathak (Eds.). Nanoparticulate Drug Delivery Systems: Recent Trends and Emerging Technologies. Boca Raton, FL: CRC Press, 2007; pp. 213-233.
89. Souto EB, Müller RH. Lipid nanoparticles (SLN and NLC) for drug delivery. In: AJ Domb, Y Tabata, MNV Ravi Kumar,and S Farber (Eds.). Nanoparticles for Pharmaceutical Applications. Stevenson Ranch, CA: American Scientifc Publishers, 2007;pp. 103-122.
90. Date AA, Joshi MD, Patravale VB. Parasitic diseases: Lipo-somes and polymeric nanoparticles versus lipid nanopar-ticles. Adv Drug Deliv Rev. 2007;59:505-521.
91. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165-196. (Pubitemid 32324113)
92. Jenning V, Gohla SH. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul. 2001;18: 149-158. (Pubitemid 32177833)
93. Goppert TM, Muller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns. J Drug Target. 2005;13: 179-187.
94. Joshi M, Patravale V. Formulation and evaluation of nano-structured lipid carrier (NLC)-based gel of Valdecoxib. Drug Dev Ind Pharm. 2006;32:911-918. (Pubitemid 44359752)
95. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242:121-128.
96. Müller RH, Radtke M, Wissing SA. Solid lipid nanopar-ticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131-S155. (Pubitemid 35379959)
97. Hu FQ, Jiang SP, Du YZ, et al. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces. 2005;45:167-173.
98. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: A literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87:1479-1488. (Pubitemid 28559628)
99. Qaddoumi MG, Ueda H, Yang J, et al. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res. 2004;21: 641-648. (Pubitemid 38457287)
100. Bu H-Z, Gukasyan HJ, Goulet L, et al. Ocular disposition, pharmacokinetics, effcacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab. 2007; 8:91-107. (Pubitemid 46218678)
101. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnol-ogy in ocular drug delivery. Drug Discov Today. 2008;13: 144-151.
102. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366:170-184.
103. González-Mira E, Marquez A, Egea MA, et al. Design and ocular tolerance of furbiprofen loaded ultrasound-engineered NLC. Colloid Surf B Biointer. 2010, (submitted).
104. Müller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm. 2004;58: 343-356.
105. Sandri G, Bonferoni MC, Gökçe EH, et al. Chitosan associated solid lipid nanoparticles: Assessment of penetration enhancement properties using RCE cell line. In: 36th Controlled Release Society Annual Meeting &Exposition, Copenhagen, Denmark, July 18-23, 2009.
106. Shen J, Wang Y, Ping Q, et al. Mucoadhesive effect of thio-lated PEG stearate and its modifed NLC for ocular drug delivery. J Control Release. 2009;137:217-223.
107. Basaran E, Demirel M, Sirmagul B, et al. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul. 2010;27:37-47.
108. Araujo J, Gonzalez E, Egea MA, et al. Nanomedicines for ocular NSAIDs: Safety on drug delivery. Nanomedicine. 2009;5:394-401.
109. Attama AA, Reichl S, Muller-Goymann CC. Sustained release and permeation of timolol from surface-modifed solid lipid nanoparticles through bioengineered human cornea. Current Eye Res. 2009;34:698-705.
110. del Pozo-Rodriguez A, Solinís MA, Gascón AR, et al. Short-and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur J Pharm Biopharm. 2009;71:181-189.
111. Li VHK, Wood RW, Kreuter J, et al. Ocular drug delivery of progesterone using nanoparticles. J Microencapul. 1986;3:213-218. (Pubitemid 17195137)
112. Xu J, Wang Y, Yue Li Y, et al. Inhibitory effcacy of intravit-real dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model. J Ocul Pharmacol Ther. 2007;23:527-540. (Pubitemid 350204675)
113. Valls R, Vega E, Garcia ML, et al. Transcorneal permeation in a corneal device of non-steroidal anti-infammatory drugs in drug delivery systems. Open Med Chem J. 2008;2: 66-71.
114. Michalowski CB, Guterres SS, Dalla Costa T. Microdi-alysis for evaluating the entrapment and release of a lipophilic drug from nanoparticles. J Pharm Biomed Anal. 2004;35:1093-1100. (Pubitemid 39140276)
115. Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedi-cine. 2009;5:90-95.
116. Solomon KD, Cheetham JK, DeGryse R, et al. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular infammation after cataract surgery. Ophthalmology. 2001;108:331-337.
117. Lekhanont K, Park CY, Smith JA, et al. Effects of topical anti-infammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. J Ocul Pharmacol Ther. 2007;23:27-34. (Pubitemid 46449297)
118. Lindstrom R, Holland E, Lane S, et al. Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation. Cornea. 2008;27:385-386; author reply 386-387. (Pubitemid 351440885)
119. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal infammation: An examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin. 2006;22:397-404. (Pubitemid 44296764)
120. Samati Y, Yuksel N, Tarimci N. Preparation and characterization of poly(D,L-lactic-co-glycolic acid) microspheres containing furbiprofen sodium. Drug Deliv. 2006;13: 105-111. (Pubitemid 43162306)
121. Coimbra PA, De Sousa HC, Gil MH. Preparation and characterization of furbiprofen-loaded poly(3-hydroxy-butyrate-co-3-hydroxyvalerate) microspheres. J Microen-capsul. 2008;25:170-178.
122. Gamisans F, Lacoulonche F, Chauvet A, et al. Flurbiprofen-loaded nanospheres: Analysis of the matrix structure by thermal methods. Int J Pharm. 1999;179:37-48. (Pubitemid 29115058)
123. Ward DA. Comparative effcacy of topically applied furbiprofen, diclofenac, tolmetin, and suprofen for the treatment of experimentally induced blood-aqueous barrier disruption in dogs. Am J Vet Res. 1996;57: 875-878.
124. González E, Ricart D, Egea MA, et al. Polyester nano-spheres as ocular ibuprofen drug delivery system. In 7th Conference and Workshop on Biological Barriers and Nanomedicine Advanced Drug Delivery and Predictive non vivo Testing Technologies; Saarbrucken, Germany, February 20-29th, 2008.
125. Hasan AS, Socha M, Lamprecht A, et al. Effect of the micro-encapsulation of nanoparticles on the reduction of burst release. Int J Pharm. 2007;344:53-61. (Pubitemid 47464826)
126. Ogawa T, Ohara K, Shimizu H.Effects of pretreatment with mydriatics on intraocular penetration of 0.1% pranopro-fen. Jpn J Ophthalmol. 1993;37:47-55. (Pubitemid 23115642)
127. Yavas GF, Ozturk F, Kusbeci T. Preoperative topical indo-methacin to prevent pseudophakic cystoid macular edema. J Cataract Refract Surg. 2007;33:804-807. (Pubitemid 46636200)
128. Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci 2000;85:530-536.
129. Calvo P, Vila-Jato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int J Pharm. 1997;153:41-50. (Pubitemid 27283332)
130. Badawi AA, El-Laithy HM, El Qidra RK, et al. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res. 2008;31:1040-1049.